Literature DB >> 29734136

Predicting neuroblastoma using developmental signals and a logic-based model.

Jennifer C Kasemeier-Kulesa1, Santiago Schnell2, Thomas Woolley3, Jennifer A Spengler4, Jason A Morrison1, Mary C McKinney1, Irina Pushel1, Lauren A Wolfe5, Paul M Kulesa6.   

Abstract

Genomic information from human patient samples of pediatric neuroblastoma cancers and known outcomes have led to specific gene lists put forward as high risk for disease progression. However, the reliance on gene expression correlations rather than mechanistic insight has shown limited potential and suggests a critical need for molecular network models that better predict neuroblastoma progression. In this study, we construct and simulate a molecular network of developmental genes and downstream signals in a 6-gene input logic model that predicts a favorable/unfavorable outcome based on the outcome of the four cell states including cell differentiation, proliferation, apoptosis, and angiogenesis. We simulate the mis-expression of the tyrosine receptor kinases, trkA and trkB, two prognostic indicators of neuroblastoma, and find differences in the number and probability distribution of steady state outcomes. We validate the mechanistic model assumptions using RNAseq of the SHSY5Y human neuroblastoma cell line to define the input states and confirm the predicted outcome with antibody staining. Lastly, we apply input gene signatures from 77 published human patient samples and show that our model makes more accurate disease outcome predictions for early stage disease than any current neuroblastoma gene list. These findings highlight the predictive strength of a logic-based model based on developmental genes and offer a better understanding of the molecular network interactions during neuroblastoma disease progression.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2018        PMID: 29734136      PMCID: PMC6016551          DOI: 10.1016/j.bpc.2018.04.004

Source DB:  PubMed          Journal:  Biophys Chem        ISSN: 0301-4622            Impact factor:   2.352


  51 in total

Review 1.  Neurotrophins: roles in neuronal development and function.

Authors:  E J Huang; L F Reichardt
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

2.  High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma.

Authors:  Johannes H Schulte; Hagen S Bachmann; Bent Brockmeyer; Katleen Depreter; André Oberthür; Sandra Ackermann; Yvonne Kahlert; Kristian Pajtler; Jessica Theissen; Frank Westermann; Jo Vandesompele; Frank Speleman; Frank Berthold; Angelika Eggert; Benedikt Brors; Barbara Hero; Alexander Schramm; Matthias Fischer
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

Review 3.  The MEK/ERK cascade: from signaling specificity to diverse functions.

Authors:  Yoav D Shaul; Rony Seger
Journal:  Biochim Biophys Acta       Date:  2006-10-19

4.  Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma.

Authors:  Yvan H Chanthery; W Clay Gustafson; Melissa Itsara; Anders Persson; Christopher S Hackett; Matt Grimmer; Elise Charron; Slava Yakovenko; Grace Kim; Katherine K Matthay; William A Weiss
Journal:  Sci Transl Med       Date:  2012-01-04       Impact factor: 17.956

5.  Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas.

Authors:  Miki Ohira; Shigeyuki Oba; Yohko Nakamura; Eriko Isogai; Setsuko Kaneko; Atsuko Nakagawa; Takahiro Hirata; Hiroyuki Kubo; Takeshi Goto; Saichi Yamada; Yasuko Yoshida; Misa Fuchioka; Shin Ishii; Akira Nakagawara
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

6.  Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.

Authors:  Sara De Brouwer; Katleen De Preter; Candy Kumps; Piotr Zabrocki; Michaël Porcu; Ellen M Westerhout; Arjan Lakeman; Jo Vandesompele; Jasmien Hoebeeck; Tom Van Maerken; Anne De Paepe; Geneviève Laureys; Johannes H Schulte; Alexander Schramm; Caroline Van Den Broecke; Joëlle Vermeulen; Nadine Van Roy; Klaus Beiske; Marleen Renard; Rosa Noguera; Olivier Delattre; Isabelle Janoueix-Lerosey; Per Kogner; Tommy Martinsson; Akira Nakagawara; Miki Ohira; Huib Caron; Angelika Eggert; Jan Cools; Rogier Versteeg; Frank Speleman
Journal:  Clin Cancer Res       Date:  2010-08-18       Impact factor: 12.531

7.  Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification.

Authors:  André Oberthuer; Frank Berthold; Patrick Warnat; Barbara Hero; Yvonne Kahlert; Rüdiger Spitz; Karen Ernestus; Rainer König; Stefan Haas; Roland Eils; Manfred Schwab; Benedikt Brors; Frank Westermann; Matthias Fischer
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

8.  Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance.

Authors:  Ozgür Sahin; Holger Fröhlich; Christian Löbke; Ulrike Korf; Sara Burmester; Meher Majety; Jens Mattern; Ingo Schupp; Claudine Chaouiya; Denis Thieffry; Annemarie Poustka; Stefan Wiemann; Tim Beissbarth; Dorit Arlt
Journal:  BMC Syst Biol       Date:  2009-01-01

Review 9.  The mTOR signaling pathway in pediatric neuroblastoma.

Authors:  Hong Mei; Ye Wang; Zhenyu Lin; Qiangsong Tong
Journal:  Pediatr Hematol Oncol       Date:  2013-05-22       Impact factor: 1.969

10.  Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas.

Authors:  Yoshiki Kaneko; Yusuke Suenaga; S M Rafiqul Islam; Daisuke Matsumoto; Yohko Nakamura; Miki Ohira; Sana Yokoi; Akira Nakagawara
Journal:  Cancer Sci       Date:  2015-05-19       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.